Supramolecular peptide vaccines: tuning adaptive immunity.

Successful immunotherapies must be designed to elicit targeted immune responses having a specifiable phenotype across many dimensions, including the phenotypes of T cells, B cells, antigen-presenting cells, and others. For synthetic or subunit vaccines, stimulation of strong enough immune responses usually requires adjuvants, which can cause local inflammation and complicate the targeting of such phenotypes. Supramolecular materials provide routes for reducing or eliminating supplemental adjuvants. Owing to their compositional controllability, supramolecular assemblies show promise for fine-tuning immune responses by adjusting combinations of material attributes including epitope content, multivalency, size, dose, and small quantities of specific adjuvants. Here we focus on supramolecular vaccines incorporating multiple epitopes in precise ratios, with an emphasis on peptides that form high-aspect ratio (i.e. fibrillar) structures.

[1]  Arthur Fridman,et al.  Titrating T‐Cell Epitopes within Self‐Assembled Vaccines Optimizes CD4+ Helper T Cell and Antibody Outputs , 2014, Advanced healthcare materials.

[2]  John A. Robinson,et al.  Synthetic Virus-Like Particles Target Dendritic Cell Lipid Rafts for Rapid Endocytosis Primarily but Not Exclusively by Macropinocytosis , 2012, PloS one.

[3]  Jeffrey A Hubbell,et al.  Engineering Approaches to Immunotherapy , 2012, Science Translational Medicine.

[4]  D. Irvine,et al.  Generation of Effector Memory T Cell–Based Mucosal and Systemic Immunity with Pulmonary Nanoparticle Vaccination , 2013, Science Translational Medicine.

[5]  C. Dobson,et al.  The amyloid state and its association with protein misfolding diseases , 2014, Nature Reviews Molecular Cell Biology.

[6]  E. Gawalt,et al.  Retaining antibodies in tumors with a self-assembling injectable system. , 2013, Molecular pharmaceutics.

[7]  I. Toth,et al.  Immunological Evaluation of Lipopeptide Group A Streptococcus (GAS) Vaccine: Structure-Activity Relationship , 2012, PloS one.

[8]  Jinglong Wu,et al.  An fMRI Study of the Neural Systems Involved in Visually Cued Auditory Top-Down Spatial and Temporal Attention , 2012, PloS one.

[9]  Rima McLeod,et al.  Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice. , 2014, Vaccine.

[10]  Krishnendu Roy,et al.  Micro and Nanoparticle‐Based Delivery Systems for Vaccine Immunotherapy: An Immunological and Materials Perspective , 2013, Advanced healthcare materials.

[11]  Jangwook P. Jung,et al.  A self-assembling peptide acting as an immune adjuvant , 2009, Proceedings of the National Academy of Sciences.

[12]  J. Hubbell,et al.  Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination , 2011, Proceedings of the National Academy of Sciences.

[13]  M. Antica,et al.  Notch signalling controls leukemic cells , 2013 .

[14]  Joel H. Collier,et al.  Gradated assembly of multiple proteins into supramolecular nanomaterials , 2014, Nature materials.

[15]  J. Hubbell,et al.  Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose , 2013, Proceedings of the National Academy of Sciences.

[16]  R. Ahmed,et al.  From vaccines to memory and back. , 2010, Immunity.

[17]  Ueli Aebi,et al.  A Nonadjuvanted Polypeptide Nanoparticle Vaccine Confers Long-Lasting Protection against Rodent Malaria1 , 2009, The Journal of Immunology.

[18]  D. Irvine,et al.  Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction , 2012, Proceedings of the National Academy of Sciences.

[19]  Melissa A. Brown,et al.  A novel synthetic adjuvant enhances dendritic cell function , 2009, Immunology.

[20]  S. Reed,et al.  Key roles of adjuvants in modern vaccines , 2013, Nature Medicine.

[21]  Honggang Cui,et al.  Self‐assembly of peptide amphiphiles: From molecules to nanostructures to biomaterials , 2010, Biopolymers.

[22]  John A. Robinson,et al.  Engineered Synthetic Virus‐Like Particles and Their Use in Vaccine Delivery , 2011, Chembiochem : a European journal of chemical biology.

[23]  Qin Guo,et al.  Protective Antibody and CD8+ T-Cell Responses to the Plasmodium falciparum Circumsporozoite Protein Induced by a Nanoparticle Vaccine , 2012, PloS one.

[24]  Jangwook P. Jung,et al.  Co-assembling peptides as defined matrices for endothelial cells. , 2009, Biomaterials.

[25]  Joel H Collier,et al.  The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. , 2013, Biomaterials.

[26]  Arnold I. Caplan,et al.  Scaling-Up of Dental Pulp Stem Cells Isolated from Multiple Niches , 2012, PloS one.

[27]  James McCluskey,et al.  More than one reason to rethink the use of peptides in vaccine design , 2007, Nature Reviews Drug Discovery.

[28]  I. Toth,et al.  Ovalbumin lipid core peptide vaccines and their CD4(+) and CD8(+) T cell responses. , 2014, Vaccine.

[29]  J. Hubbell,et al.  Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. , 2014, Biomaterials.

[30]  Ronald N Germain,et al.  Vaccines and the future of human immunology. , 2010, Immunity.

[31]  Ashutosh Kumar Singh,et al.  Engineering vaccines and niches for immune modulation. , 2014, Acta biomaterialia.

[32]  Wah Chiu,et al.  Interbilayer-Crosslinked Multilamellar Vesicles as Synthetic Vaccines for Potent Humoral and Cellular Immune Responses , 2011, Nature materials.

[33]  W. Paul,et al.  Differentiation of effector CD4 T cell populations (*). , 2010, Annual review of immunology.

[34]  John A. Robinson,et al.  Synthetic virus-like particles from self-assembling coiled-coil lipopeptides and their use in antigen display to the immune system. , 2007, Angewandte Chemie.

[35]  Ray Cummings,et al.  Vaccine stabilization: research, commercialization, and potential impact. , 2011, Vaccine.

[36]  Matthew Tirrell,et al.  Self‐Assembled Peptide Amphiphile Micelles Containing a Cytotoxic T‐Cell Epitope Promote a Protective Immune Response In Vivo , 2012, Advanced materials.

[37]  N. Petrovsky,et al.  Vaccine adjuvants: Current state and future trends , 2004, Immunology and cell biology.

[38]  S. Crotty,et al.  Follicular helper CD4 T cells (TFH). , 2011, Annual review of immunology.

[39]  Satish Mishra,et al.  Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope. , 2012, Biomaterials.

[40]  J. Rudra,et al.  Antigenic peptide nanofibers elicit adjuvant-free CD8⁺ T cell responses. , 2014, Vaccine.

[41]  James J. Moon,et al.  Biomaterials for Nanoparticle Vaccine Delivery Systems , 2014, Pharmaceutical Research.

[42]  R. Riek,et al.  Biology of amyloid: structure, function, and regulation. , 2010, Structure.

[43]  Matthew V. Tirrell,et al.  Peptide Amphiphile Micelles Self-Adjuvant Group A Streptococcal Vaccination , 2014, The AAPS Journal.

[44]  Joel H Collier,et al.  Modulating adaptive immune responses to peptide self-assemblies. , 2012, ACS nano.

[45]  Shuguang Zhang,et al.  Designer Self-Assembling Peptide Nanofiber Biological Materials , 2010 .

[46]  J. Collier,et al.  A Self‐Adjuvanting Supramolecular Vaccine Carrying a Folded Protein Antigen , 2013, Advanced healthcare materials.

[47]  Kenta Moriwaki,et al.  The RIP1/RIP3 Necrosome Forms a Functional Amyloid Signaling Complex Required for Programmed Necrosis , 2012, Cell.

[48]  G. Goldman,et al.  Functional Characterization of an Aspergillus fumigatus Calcium Transporter (PmcA) that Is Essential for Fungal Infection , 2012, PloS one.

[49]  Joel H Collier,et al.  Engaging adaptive immunity with biomaterials. , 2014, Journal of materials chemistry. B.

[50]  T. Lebien,et al.  B lymphocytes: how they develop and function. , 2008, Blood.

[51]  R. Coffman,et al.  Vaccine adjuvants: putting innate immunity to work. , 2010, Immunity.

[52]  Jing-Wen Ma,et al.  A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy. , 2012, Journal of the American Chemical Society.

[53]  M. Skwarczynski,et al.  Self-adjuvanting vaccine against group A streptococcus: application of fibrillized peptide and immunostimulatory lipid as adjuvant. , 2014, Bioorganic & medicinal chemistry.

[54]  Robert J Citorik,et al.  Synthesis and patterning of tunable multiscale materials with engineered cells , 2014, Nature materials.

[55]  A. Collins,et al.  A Temporal Model of Human IgE and IgG Antibody Function , 2013, Front. Immunol..

[56]  I. Toth,et al.  Increased adjuvant activity of minimal CD8 T cell peptides incorporated into lipid‐core‐peptides , 2004, Immunology and cell biology.

[57]  M. Tirrell,et al.  Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists , 2010, Expert review of vaccines.

[58]  Darrell J Irvine,et al.  Engineering synthetic vaccines using cues from natural immunity. , 2013, Nature materials.

[59]  Enhancing Ef fi cacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes , 2014 .